MAJOR PHASE 1 UPDATE! Joey Bose Cytonics Corporation #Cytonics #drugdevelopment #clinicaltrials #arthritis
President & CEO of Cytonics | Johns Hopkins School of Medicine | Moving From Insurmountable Challenge To Almost Certain Failure With Unbridled Enthusiasm
🎉 Major Phase 1 Study Milestone Achieved! 🚨 First Nine Patients Complete Study with No Adverse Events We’re thrilled to share a major milestone in the development of CYT-108, Cytonics Corporation's groundbreaking biologic therapy for osteoarthritis: ✅ The first nine patients in our Phase 1 clinical trial have completed the study, including dosing on Day 0 and Day 90, with follow-up through Day 180. 🛡️ Most importantly, no drug-related adverse events were reported, affirming CYT-108’s safety profile and paving the way for the next stage of development. 🔬 Why This Matters CYT-108 is a recombinant variant of alpha-2-macroglobulin (A2M), a naturally occurring protein that protects cartilage by neutralizing enzymes that degrade it. Engineered to target and inhibit the proteases responsible for cartilage damage, CYT-108 is positioned as a potential disease-modifying therapy—a first for osteoarthritis. 🚀 Next Steps: Advancing to Phase 2 This milestone brings us closer to initiating Phase 2 clinical trials, where we will evaluate CYT-108’s efficacy in a larger group of patients and gather data on pain reduction and joint function improvement. #Cytonics #arthritis #clinicaltrials #regenerativemedicine #drugdevelopment
Very informative
Love this
Great breakthrough!
Tricyrcle CEO | MicroBlocks Partnerships | Strategic Advisor
1moExciting milestone indeed! Hurry up through the next trial phases before I need this therapy! 😂 Major kudos Gaetano Scuderi, MD 🤩